Business Context and Reporting Period
This Form 8-K Current Report was filed by CalciMedica, Inc. on January 10, 2025. The report details corporate governance changes involving the departure of a director and the appointment of a new director, effective January 15, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Eric Bjerkholt resigned as a member of the Board of Directors, Chair of the Audit Committee, and member of the Audit Committee. The resignation is effective January 15, 2025, and is not the result of any disagreement with the Company.
- Director Appointment: Alan Glicklich, M.D., was appointed as a Class I director effective January 15, 2025, with a term expiring at the 2027 annual meeting of stockholders.
Guidance, Outlook, and Compensation
The filing does not provide guidance, outlook, management commentary on operations, or discuss risks and contingencies. However, it discloses the following compensatory arrangements for the new director:
- Cash Retainer: $40,000 annual cash retainer, pro-rated based on days served.
- Stock Option: An option to purchase 20,000 shares of common stock, vesting monthly over a three-year period subject to continuous service.
- Indemnity: Dr. Glicklich will enter into the Company's standard form of Indemnity Agreement for directors.
Investor Verification Checklist
- Verify the effective date of the board composition change (January 15, 2025).
- Confirm the total equity dilution impact of the 20,000 share option grant to Dr. Glicklich.
- Review the Company's recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the Audit Committee composition following Dr. Bjerkholt's departure as Chair.